Fountainhead AM LLC Has $518,000 Stake in Pfizer Inc. (NYSE:PFE)

Fountainhead AM LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 4.7% in the 1st quarter, Holdings Channel.com reports. The fund owned 20,448 shares of the biopharmaceutical company’s stock after purchasing an additional 922 shares during the quarter. Fountainhead AM LLC’s holdings in Pfizer were worth $518,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Bessemer Group Inc. boosted its position in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK raised its position in shares of Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Pfizer in the first quarter worth about $8,283,000. Alta Advisers Ltd grew its stake in shares of Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company’s stock worth $809,000 after purchasing an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC boosted its position in Pfizer by 8.7% during the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company’s stock valued at $3,176,000 after acquiring an additional 10,051 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on PFE shares. Leerink Partners decreased their target price on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. HSBC reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Finally, TD Cowen reduced their price target on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.55.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.12 during mid-day trading on Friday, reaching $24.46. The company’s stock had a trading volume of 36,271,002 shares, compared to its average volume of 41,912,175. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a fifty day moving average of $24.07 and a two-hundred day moving average of $24.74. The firm has a market capitalization of $139.06 billion, a PE ratio of 17.72, a P/E/G ratio of 0.90 and a beta of 0.58.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. Pfizer’s revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.03%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.